VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The potential use of luxeptinib in MCL

Alexey V. Danilov, MD, PhD, City of Hope, Duarte, CA, comments on the mechanism of action of luxeptinib (formerly CG-806), a BTK/SYK inhibitor currently under investigation in a Phase I trial for the treatment of mantle cell lymphoma (MCL). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter